New antibody combo JST-018 enters first human safety trial
Disease control
Recruiting now
This Phase 1 study is testing whether a single injection of JST-018, a mix of three monoclonal antibodies, is safe and tolerable in 48 healthy adults aged 18 to 55. Participants will be monitored for side effects, drug levels in the blood, and immune responses over one year. This…
Phase: PHASE1 • Sponsor: Just-Evotec Biologics • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC